Why this matters
The FDA's 2026 final premarket guidance and AAMI TIR57:2016/(R)2023 both require a structured, documented threat model. Reviewers reject generic 'STRIDE applied to a SaMD' write-ups. This kit gives you a repeatable methodology you can run on your own device today and present to a reviewer with confidence.
Key takeaway: A threat model is not a one-time deliverable. It is a living artifact that gets updated every time the architecture changes - new interface, new dependency, new deployment target.
